Detection peptide fragment combination for carrying out relative quantitative analysis on GSK3beta protein in serum specimen based on PRM targeted proteomics as well as extraction method and application of detection peptide fragment combination

A detection peptide combination for GSK3β protein in serum and urine using PRM targeted proteomics addresses sensitivity limitations, enabling accurate relative quantitative analysis and correlating with kidney damage in diabetic nephropathy.

CN119060133APending Publication Date: 2024-12-03THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411317340.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-20
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

Current methods for detecting GSK3β protein in body fluids, particularly ELISA, are limited in sensitivity and detection range, especially for patients with low expression levels, and there is a lack of standardized detection peptides for GSK3β in mass spectrometry-based proteomics.

Method used

A detection peptide combination comprising sequences QTLPVIYVK, TPPEAIALCSR, and LLEYTPTAR is used for relative quantitative analysis of GSK3β protein in serum and urine specimens through PRM targeted proteomics, involving sample treatment with lysis solution, mass spectrometry data collection, and analysis using specific software to establish a spectrum database.

Benefits of technology

The method provides high sensitivity and specificity for detecting GSK3β protein, enabling accurate relative quantitative analysis in serum and urine specimens, correlating with kidney damage in diabetic nephropathy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119060133A_ABST
    Figure CN119060133A_ABST
Patent Text Reader

Abstract

The invention relates to a detection peptide fragment combination for carrying out relative quantitative analysis on GSK3beta protein in a serum sample based on PRM targeted proteomics as well as an extraction method and application of the detection peptide fragment combination, and can effectively solve the problem of carrying out relative quantitative analysis on GSK3beta protein in serum or urine samples of patients with diabetic nephropathy through a PRM targeted proteomics technology. According to the technical scheme, the detection peptide fragment combination of the GSK3beta is provided, the detection peptide fragment combination is peptide fragments with the sequences of QTLPVIYVK, TPPEAIALCSR and LLEYTPTAR, a very good peptide fragment sequence and a standard substance are provided for peptide fragment detection of the GSK3beta protein in serum or urine, the sequence is obtained through detection and autonomous analysis by means of the GSK3beta protein, synthesis of the peptide fragments is conducted, and the detection peptide fragment combination of the GSK3beta protein is obtained. A subsequent detection result shows that peptide fragments of GSK3beta with high expression abundance in serum and urine are different, and the method is an innovation on a method for carrying out relative quantitative analysis on GSK3beta protein in a serum sample based on PRM targeted proteomics.
Need to check novelty before this filing date? Find Prior Art

Description

1. Technical Field

[0001] The present invention relates to the field of biomedicine technology, and in particular to a detection peptide combination for performing relative quantitative analysis of GSK3β protein in serum samples based on PRM targeted proteomics, and an extraction method and application thereof. 2. Background Technology

[0002] Currently, the clinical assessment of renal function in diabetic nephropathy is usually performed by calculating the estimated glomerular filtration rate (eGFR), and renal damage is usually assessed by examining the urine albumin to creatinine ratio in a random urine sample. There are some potential pitfalls in using eGFR as a marker for early diagnosis of DKD. First, serum creatinine levels are affected by muscle mass and dietary patterns (especially meat intake), which may interfere with the calculation of eGFR. Second, in some cases, the formula used may also lead to inaccurate results.

[0003] Albuminuria is considered a marker of kidney damage, particularly glomerular dysfunction. Calculation of UACR by examining albumin and creatinine levels in a random urine sample is the current clinical standard. However, urinary albumin excretion may also be increased for reasons other than DKD, such as physical activity, dietary patterns, infection, fever, congestive heart failure, hyperglycemia, menstruation, and hypertension. There is growing interest in using alternative biomarkers other than urinary albumin and creatinine, including protein-based biomarkers present in urine, blood, and kidney tissue samples, in detecting early DKD.

[0004] GSK3β (glycogen synthase kinase 3β) is a highly conserved threonine / serine kinase that activates glycogen synthase. As a key molecule in the glucose metabolism pathway, GSK3β participates in a variety of cellular activities, plays a key role in a variety of diseases, and is also a biomarker indicating the progression of DKD. Studies have shown that the expression level of GSK3β is positively correlated with kidney damage, especially the degree of kidney damage in diabetic nephropathy, and can be used as a biomarker for diabetic kidney damage. However, the current detection method for GSK3β in body fluids is only ELISA, and the detection range is limited. For patients with low expression levels of GSK3β in serum, especially urine, the sensitivity and detection range of ELISA are obviously insufficient, and the ELISA method is highly dependent on antibodies to GSK3β, which has certain limitations. Therefore, the improvement and innovation of GSK3β detection methods are currently an urgent problem to be solved.

[0005] Proteomics refers to the discipline of large-scale, high-throughput research on the full set of proteins expressed in a cell, tissue or species. In the past decade, the rapid development of mass spectrometry technology has greatly promoted the progress of proteomics, and mass spectrometry-based proteomics has become an indispensable technical means in the field of protein research. Proteomics technology can be used to identify or quantify proteins and post-translational modification sites (such as phosphorylation) in biological samples on a large scale, and then valuable information and rules can be mined from high-throughput data analysis, providing clues and basis for the exploration of functional mechanisms.

[0006] Mass spectrometry analysis includes a variety of different strategies, and it is necessary to select the appropriate experimental scheme according to the specific research purpose in order to achieve the best experimental data. According to the different mass spectrometry scanning methods, it can be roughly divided into three categories: data-dependent acquisition (DDA), data-independent acquisition (SWATH / DIA) and targeted analysis (SRM, PRM). Large-scale proteome identification and quantification usually use DDA and DIA analysis methods, which can obtain qualitative or quantitative information of up to thousands of proteins at the same time, and then mine the obtained data in order to discover meaningful scientific problems. This strategy is called "discovery proteomics". For selected, interesting proteins or peptides, it is best to use targeted analysis methods (Targeted proteomics) to verify specific scientific hypotheses. For example, SRM technology and the recently popular PRM technology have the advantages of being independent of antibodies, high sensitivity and good specificity, and are called "Western Blot" in the field of mass spectrometry.

[0007] PRM technology uses a spectral library based on samples containing target proteins and peptides or synthesized standard peptides to establish a specific mass spectrometry acquisition method for target proteins and peptides, monitor the target peptides in the sample, and achieve relative or absolute quantification. Figure 1 . Simply put, the target peptide is screened out in the quadrupole (Q1) of the mass spectrometer and sent to the collision chamber Q2 for fragmentation. All fragment ions are scanned by the mass analyzer (Orbitrap or TOF) to produce a high-resolution secondary mass spectrum. Quantification is achieved by extracting the daughter ion information. At the same time, the secondary mass spectrum can also be searched in the database for identification. Currently, there is a lack of standardized detection peptides for GSK3β on the market. There are no reports on the peptide sequences of GSK3β with high abundance in patient serum or urine, and there are no reports on the results of GSK3β peptide detection in patient serum or urine. III. Summary of the invention

[0008] In view of the above situation, in order to solve the defects of the prior art, the purpose of the present invention is to provide a detection peptide combination and its extraction method and application for relative quantitative analysis of GSK3β protein in serum specimens based on PRM targeted proteomics, which can effectively solve the problem of relative quantitative analysis of GSK3β protein in serum or urine specimens of patients with diabetic nephropathy through PRM targeted proteomics technology.

[0009] The technical solution solved by the present invention is to provide a method for relative quantitative analysis of GSK3β protein in serum specimens based on PRM targeted proteomics, the method comprising: firstly, adding lysis solution (1% SDC, 100mM Tris-HCl, 10mM TCEP at pH=8.5, 40mM CAA) to the sample through sample treatment, secondly, using a Q Exactive HF mass spectrometer connected in series with an UltiMate 3000RSLCnano liquid phase liquid chromatography-mass spectrometry system to collect mass spectrometry data, then using MaxQuant (V1.6.6) software to retrieve DDA mass spectrometry data, and finally using Skyline software to analyze the PRM mass spectrometry data, establishing a spectrum database based on the DDA data analysis results, and extracting quantitative information of the target protein and peptide segment.

[0010] Provided is a GSK3β detection peptide combination, wherein the detection peptide combination is a peptide with sequences of QTLPVIYVK, TPPEAIALCSR, and LLEYTPTAR, as shown in SEQ ID NO.1-3.

[0011] The application of the detection peptide combination in preparing a kit for detecting GSK3β in diabetic nephropathy serum.

[0012] The application of the detection peptide combination in the preparation of a diabetic nephropathy urine detection GSK3β kit.

[0013] The present invention provides very good peptide sequences and standards for peptide detection of GSK3β protein in serum or urine. The GSK3β protein is used for detection, the sequence is independently analyzed, and the peptide synthesis is performed. Subsequent test results show that the peptides of GSK3β with high expression abundance in serum and urine are different. This is an innovation in the method of relative quantitative analysis of GSK3β protein in serum specimens based on PRM targeted proteomics. IV. Description of the drawings

[0014] Figure 1 It is a schematic diagram of the PRM principle of the present invention.

[0015] Figure 2 This is the PRM technology roadmap of the present invention.

[0016] Figure 3 It is a peptide segment with better signal response in the present invention.

[0017] Figure 4 The present invention finally determined 8 peptide segments with better signals of the standard protein.

[0018] Figure 5 The results of mass spectrometry analysis of 8 peptide segments in the present invention are shown.

[0019] Figure 6 This is the detection result of the GSK3β peptide segment in the serum of the present invention.

[0020] Figure 7 It is the peptide expression level of GSK3β detected in urine of the present invention.

[0021] Figure 8 The peptide expression level of GSK3β in urine of the present invention is positively correlated with urine protein uACR.

[0022] Fig. 9 The peptide expression level of GSK3β in urine of the present invention is negatively correlated with the eGFR. V. Specific implementation methods

[0023] The specific implementation modes of the present invention are further described in detail below in conjunction with the accompanying drawings.

[0024] Example 1

[0025] The present invention, when implemented, comprises the following steps:

[0026] 1) Select peptides with better signal response

[0027] Take 3ug of standard protein for protein denaturation, reduction alkylation, trypsin digestion and SDB desalting, drain and store at -20°C, add lysis buffer: 1% SDC, 100mM Tris-HCl, 10mM TCEP at pH=8.5, 40mM CAA to the sample, load the sample for detection, detection instrument: timsTOF pro, DDA acquisition mode, 30min time gradient, sample loading amount 50ng, and obtain peptides with better signal response;

[0028] 2) Determine 8 peptides with good signals from the standard protein

[0029] The mass spectrometry data of the peptides with good signal response obtained in step 1) were collected using a Q Exactive HF mass spectrometer connected in series with an UltiMate 3000RSLCnano liquid phase LC-MS system, and the samples were loaded for detection. The detection instrument was timsTOF pro, PRM acquisition mode, 30 min time gradient, and the loading amount was 50 ng. Based on the peptide detection signal, missed cleavage, and uniqueness, 8 peptides with good signals of the standard protein were finally determined;

[0030] 3) Select the three peptides with the best response

[0031] The DDA mass spectrometry data of 8 peptides with good signals of the standard protein obtained in step 2) were retrieved by MaxQuant (V1.6.6) software, and the samples were designed as follows: S1 single serum sample without enrichment, S2 single serum sample without enrichment + 10ng standard protein, U1 single urine sample, U2 single urine sample + 10ng standard protein, and then each group of samples was tested separately. The detection instrument was timsTOF pro, PRM acquisition mode, 30min time gradient, and finally 3 peptides with detection signals were obtained;

[0032] 4) Finally, Skyline software was used to analyze the PRM mass spectrometry data, and a spectrum database was established based on the DDA data analysis results to extract the quantitative information of the target protein and peptide.

[0033] In the step 2), the 8 peptide sequences with good signals of the standard protein are: TTSFAESCKPVQQPSAFGSMK, VTTVVATPGQGPDRPQEVSYTDTK, QTLPVIYVK, LYMYQLFR, SLAYIHSFGICHR, DIKPQNLLLDPDTAVLK, TPPEAIALCSR, LLEYTPTAR, as shown in SEQ ID NO.1-8.

[0034] In the step 3), the three peptide sequences with detection signals are: QTLPVIYVK, TPPEAIALCSR, LLEYTPTAR, as shown in SEQ ID NO.1-3.

[0035] In the step 2-3), the detection process is as follows: the peptide sample is injected into a C18 Trap column (75 μm×2 cm, 3 μm particle size, pore size, Thermo), and on a reverse phase C18 analytical column (75 μm × 15 cm, 1.7 μm particle size, The samples were separated in a 50% pore size, Ion Opticks) and the mobile phase A (0.1% formic acid) and the mobile phase B (0.1% formic acid / 99.9% acetonitrile) were used to establish a separation gradient with a time of 0 min, 15 min and 30 min.

[0036] The present invention provides a method for relative quantitative analysis of GSK3β protein in serum or urine specimens using PRM targeted proteomics technology. In order to establish a specific mass spectrometry acquisition method for target proteins and peptides, a peptide combination for detecting GSK3β signals in serum or urine of diabetic nephropathy patients is found. Three peptides have detection signals in the test samples. These three peptides are used for detection in more samples, and it is found that the peptide TPPEAIALCSR has the most obvious detection abundance in patient serum; the peptide LLEYTPTAR has the most obvious detection abundance in patient urine. It can be effectively used in relative quantitative analysis of GSK3β protein in serum or urine specimens of patients with diabetic nephropathy. The relevant test data are as follows:

[0037] 1. Select peptides with better signal response

[0038] The GSK3β standard protein was used for the experiment, and peptides with better signal response were selected.

[0039] Experimental steps: 3ug standard protein was taken for protein denaturation, reduction alkylation, trypsin digestion and SDB desalting, and then stored at -20°C after being drained. Detection instrument: timsTOF pro, DDA acquisition mode, 30min time gradient, sample loading amount 50ng.

[0040] Test results: A total of 20 unique peptides were detected in the standard protein GSK3B (P49841), and the signal value was very high. The specific peptide sequences are shown in Table 1:

[0041] Table 1 Peptide sequences and detection signal intensity

[0042] Peptide sequence Detect signal strength AKQTLPVIYVK 1.58E+07 DIKPQNLLLDPDTAVLK 9.28E+07 GQTNNAASASASNST 1.13E+05 IQAAASTPTNATAASDANTGDR 2.84E+07 IQAAASTPTNATAASDANTGDRGQTNNAASASASNST 9.56E+05 LCDSGELVAIK 4.76E+07 LCDSGELVAIKK 7.65E+07 LLEYTPTAR 7.49E+07 LTPLEACAHSFFDELR 1.33E+07 LTPLEACAHSFFDELRDPNVK 6.98E+07 LYMYQLFR 4.05E+07 PQNLLLDPDTAVLK 5.06E+05 PVQQPSAFGSMK 2.43E+06 QTLVVY 6.60E+07 SLAYIHSFGICHR 4.34E+07 TPPEAIALCSR 1.08E+08 TTSFAESCKPVQQPSAFGSMK 6.20E+07 VIGNGSFGVVYQAK 5.86E+07 VTTVVATPGQGPDR 1.51E+06 VTTVVATPGQGPDRPQEVSYTDTK 6.44E+07

[0043] 2. Determine 8 peptides with good signals from the standard protein

[0044] The PRM acquisition method was established based on the peptide response signal of the standard protein GSK3B.

[0045] Detection instrument: timsTOF pro, PRM acquisition mode, 30 min time gradient, sample loading amount 50 ng.

[0046] Test results: According to the peptide detection signal, missed cutting and uniqueness, 8 peptides with good signals of the standard protein were finally determined. The sequences of these 8 peptides are: TTSFAESCKPVQQPSAFGSMK, VTTVVATPGQGPDRPQEVSYTDTK, QTLPVIYVK, LYMYQLFR, SLAYIHSFGICHR, DIKPQNLLLDPDTAVLK, TPPEAIALCSR, LLEYTPTAR.

[0047] 3. Select the three peptides with the best response

[0048] The PRM acquisition method confirmed in the third test was verified on the sample itself, and the three peptides with the best response were selected as stable isotope standard peptides based on the test results to achieve absolute quantification.

[0049] Sample design: S1 (single serum sample without enrichment), S2 (single serum sample without enrichment + 10ng standard protein), U1 (single urine sample), U2 (single urine sample + 10ng standard protein). Detection instrument: timsTOF pro, PRM acquisition mode, 30min time gradient.

[0050] Mass spectrometry detection method: Mass spectrometry analysis was performed using Bruker's timsTOF Pro LC / MS system, which is an ion mobility (TIMS)-quadrupole-time of flight mass spectrometer. The UltiMate 3000RSLCnano system (Thermo) was connected to the timsTOF Pro via a CaptiveSpray nanoliter ion source (Bruker). The peptide sample was injected into a C18 Trap column (75 μm × 2 cm, 3 μm particle size, pore size, Thermo), and on a reverse phase C18 analytical column (75 μm × 15 cm, 1.7 μm particle size, The separation gradient was established by mobile phase A (0.1% formic acid) and mobile phase B (0.1% formic acid / 99.9% acetonitrile).

[0051] The mass spectrometer was operated in PASEF mode with the capillary voltage set to 1500 V. The acquisition range for MS1 and MS2 spectra was set to 100 to 1700 m / z. The ion mobility 1 / K0 range was set to 0.75 to 1.4 Vs / cm^2. The accumulation time was set to 166 ms and the ramp time was set to 100 ms. The acquisition cycle time was 1.9 s, including one MS1 full scan and 10 PASEF MS2 scans. Singly charged precursor ions were excluded by ion mobility characteristics. Precursor ions with signals above 1000 were selected for fragmentation. Target intensity was set to 10000. The isolation windows of the quadrupole were set to 2.0 Da (m / z 700) and 3.0 Da (m / z 800). The collision energy was set to decrease linearly from 59 eV at 1 / K0 = 1.6 Vs / cm^2 to 20 eV at 1 / K0 = 0.6 Vs / cm^2 according to the ion mobility. The dynamic exclusion time was set to 0.4 min.

[0052] When the mass spectrometer was used for data acquisition in prmPASEF mode, the target ion acquisition was set up using timsControl software based on information such as the mass-to-charge ratio and ion mobility of the target ions; parameters such as LC conditions, scanning range, and collision energy were kept consistent with those in the DDA pre-test.

[0053] Test results: Among the 8 peptides, 3 peptides had detection signals in the test samples. The sequences of the 3 peptides were QTLPVIYVK, TPPEAIALCSR, and LLEYTPTAR. S represents serum samples, and U represents urine samples. These three peptides were used to test more samples, and it was found that the peptide TPPEAIALCSR had the most obvious abundance in the patient's serum, and the peptide LLEYTPTAR had the most obvious abundance in the patient's urine.

[0054] 4. Serum or urine specimen testing in patients with diabetic nephropathy

[0055] The peptide segments independently discovered and synthesized by the present invention were used to detect serum or urine specimens of patients with diabetic nephropathy, and it was found that the expression of GSK3β in serum increased with the increase of the patient's urine protein level; the expression of GSK3β in urine was positively correlated with the patient's urine protein level and negatively correlated with the glomerular filtration rate; it has the ability to indicate kidney damage in diabetic nephropathy.

[0056] The results of the GSK3β peptide test in serum are as follows Figure 6 As shown in Figure 2, the peptide expression levels of GSK3β detected in urine are as follows: Figure 7 As shown in Figure 2, the expression level of GSK3β peptide in urine is related to urine protein uACR. Figure 8As shown in the figure, the expression level of GSK3β peptide in urine is positively correlated with urinary protein uACR; the expression level of GSK3β peptide in urine is positively correlated with glomerular filtration rate (eGFR) as shown in the figure. Fig. 9 As shown, the expression level of GSK3β peptide in urine is negatively correlated with eGFR.

[0057] V. Conclusion

[0058] The present invention provides an application of relative quantitative analysis of GSK3β protein in serum or urine specimens of patients with diabetic nephropathy based on PRM targeted proteomics technology. First, by sample processing, a lysate (1% SDC / 100mM Tris-HCl, pH=8.5 / 10mM TCEP / 40mM CAA) is added to the sample. Further, a liquid-mass spectrometer system of a Q Exactive HF mass spectrometer connected in series with an UltiMate 3000RSLCnano liquid phase is used to collect mass spectrometry data. Subsequently, the DDA mass spectrometry data is retrieved by the MaxQuant (V1.6.6) software. Finally, the PRM mass spectrometry data is analyzed using the Skyline software, a spectrum database is established based on the DDA data analysis results, and quantitative information of the target protein and peptide is extracted. The above results show that the PRM targeted proteomics technology can be used for relative quantitative analysis of GSK3β protein in serum or urine specimens, and a new idea is opened up for establishing a specific mass spectrometry acquisition method for target proteins and peptides, monitoring the target peptides in the sample, and realizing relative or absolute quantification.

[0059] Currently, there is a lack of standardized peptides for GSK3β detection on the market, and there are no reports on the peptide sequences of GSK3β with high abundance in patient serum or urine. There are also no reports on the results of GSK3β peptide detection in patient serum or urine. Our test provides very good peptide sequences and standards for peptide detection of GSK3β protein in serum or urine. This standard peptide is the sequence we analyzed independently using GSK3β protein for detection, and the peptides were synthesized. Subsequent test results showed that the peptides of GSK3β with high abundance in serum and urine are different.

[0060] It should be pointed out that the above is only a preferred embodiment of the present invention and does not limit the present invention in any form. Any technician familiar with the profession can make changes or modify the technical contents disclosed above into equivalent embodiments with equivalent changes without departing from the scope of the technical solution of the present invention, which all fall within the protection scope of the present invention.

Claims

1. A detection peptide combination for relative quantitative analysis of GSK3β protein in serum samples based on PRM targeted proteomics, characterized in that: The detection peptide segment combination is a peptide segment with the sequences of QTLPVIYVK, TPPEAIALCSR, and LLEYTPTAR.

2. The method for extracting a combination of detection peptides for relative quantitative analysis of GSK3β protein in serum samples based on PRM targeted proteomics according to claim 1, characterized in that: First, the samples were treated by adding lysis buffer: 1% SDC, 100 mM Tris-HCl, 10 mM TCEP at pH=8.5, and 40 mM CAA. Then, the mass spectrometry data were collected using a Q Exactive HF mass spectrometer connected in series with an UltiMate 3000 RSLCnano liquid phase LC-MS system. The DDA mass spectrometry data were then retrieved using MaxQuantV1.6.6 software. Finally, the PRM mass spectrometry data were analyzed using Skyline software. A spectral database was established based on the DDA data analysis results to extract the quantitative information of the target proteins and peptides.

3. The method for extracting a detection peptide combination for relative quantitative analysis of GSK3β protein in serum samples based on PRM targeted proteomics according to claim 2, characterized in that: The following steps are involved: 1) Select peptides with better signal response Take 3 ug of standard protein for protein denaturation, reduction alkylation, trypsin digestion and SDB desalting, drain and store at -20°C, add lysis buffer: 1% SDC, 100 mM Tris-HCl, 10 mM TCEP at pH=8.5, 40 mM CAA to the sample, load the sample for detection, detection instrument: timsTOF pro, DDA acquisition mode, 30 min time gradient, sample loading amount 50 ng, and obtain peptides with better signal response; 2) Determine 8 peptides with good signals from the standard protein The mass spectrometry data of the peptides with good signal response obtained in step 1) were collected using a Q Exactive HF mass spectrometer connected in series with an UltiMate 3000 RSLCnano liquid phase LC-MS system, and the samples were loaded for detection. The detection instrument was timsTOF pro, PRM acquisition mode, 30 min time gradient, and the loading amount was 50 ng. Based on the peptide detection signal, missed cleavage, and uniqueness, 8 peptides with good signals of the standard protein were finally determined. 3) Select the three peptides with the best response The DDA mass spectrometry data of 8 peptides with good signals of the standard protein obtained in step 2) were retrieved by MaxQuant V1.6.6 software, and the samples were designed as follows: S1 single serum sample without enrichment, S2 single serum sample without enrichment + 10 ng standard protein, U1 single urine sample, U2 single urine sample + 10 ng standard protein, and then each group of samples was tested separately. The detection instrument was: timsTOF pro, PRM acquisition mode, 30 min time gradient, and finally 3 peptides with detection signals were obtained; 4) Finally, Skyline software was used to analyze the PRM mass spectrometry data, and a spectrum database was established based on the DDA data analysis results to extract the quantitative information of the target protein and peptide.

4. The method for extracting a detection peptide combination for relative quantitative analysis of GSK3β protein in serum samples based on PRM targeted proteomics according to claim 3, characterized in that: In the step 2), the 8 peptide sequences with good signals of the standard protein are: TTSFAESCKPVQQPSAFGSMK, VTTVVATPGQGPDRPQEVSYTDTK, QTLPVIYVK, LYMYQLFR, SLAYIHSFGICHR, DIKPQNLLLDPDTAVLK, TPPEAIALCSR, and LLEYTPTAR.

5. The method for extracting a combination of detection peptides for relative quantitative analysis of GSK3β protein in serum samples based on PRM targeted proteomics according to claim 3, characterized in that: In the step 3), the three peptide sequences with detection signals are: QTLPVIYVK, TPPEAIALCSR, and LLEYTPTAR.

6. The method for extracting a detection peptide combination for relative quantitative analysis of GSK3β protein in serum samples based on PRM targeted proteomics according to claim 3, characterized in that: In the steps 2-3), the detection process is as follows: the peptide sample is injected by an automatic sampler and bound to a C18 Trap column: 75 µm × 2 cm, 3 µm particle size, 100 Å pore size, Thermo, and separated in a reversed phase C18 analytical column: 75 µm × 15 cm, 1.7 µm particle size, 100 Å pore size, IonOpticks, and a separation gradient of 0 min, 15 min, and 30 min is established by mobile phase A 0.1% formic acid and mobile phase B 0.1% formic acid + 99.9% acetonitrile.

7. Use of the detection peptide combination according to claim 1 in preparing a kit for detecting GSK3β in diabetic nephropathy serum.

8. Use of the detection peptide combination according to claim 1 in the preparation of a kit for detecting GSK3β in urine of diabetic nephropathy.

9. Use of the detection peptide combination extracted by the extraction method according to any one of claims 2 to 6 in the preparation of a kit for detecting GSK3β in diabetic nephropathy serum.

10. Use of the detection peptide combination according to any one of claims 2 to 6 in the preparation of a kit for detecting GSK3β in urine of diabetic nephropathy.